Document Type
Article
Publication Date
1-1-2019
Publication Title
Front Oncol
Abstract
Malignant Mesothelioma (MM) is a rare and highly aggressive cancer that develops from mesothelial cells lining the pleura and other internal cavities, and is often associated with asbestos exposure. To date, no effective treatments have been made available for this pathology. Herein, we propose a novel immunotherapeutic approach based on a unique vaccine targeting a series of antigens that we found expressed in different MM tumors, but largely undetectable in normal tissues. This vaccine, that we term p-Tvax, is comprised of a series of immunogenic peptides presented by both MHC-I and -II to generate robust immune responses. The peptides were designed using
Clinical Institute
Cancer
Department
Oncology
Department
Earle A. Chiles Research Institute
Recommended Citation
Hoffmann, Peter R; Hoffmann, Fukun W; Premeaux, Thomas A; Fujita, Tsuyoshi; Soprana, Elisa; Panigada, Maddalena; Chew, Glen M; Richard, Guilhem; Hindocha, Pooja; Menor, Mark; Khadka, Vedbar S; Deng, Youping; Moise, Lenny; Ndhlovu, Lishomwa C; Siccardi, Antonio; Weinberg, Andrew D; De Groot, Anne S; and Bertino, Pietro, "Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models." (2019). Articles, Abstracts, and Reports. 1983.
https://digitalcommons.providence.org/publications/1983
